Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ukko logo — On a mission to solve food allergies and sensitivities

Ukko

On a mission to solve food allergies and sensitivities

Founded 2016 Israel Israel 56 employees Series B Total: $47.70M Biotechnology, Food and Beverage +1

General Information

Company Name Ukko
Founded Year 2016
Location Israel Israel
Employees 56
Industries Biotechnology, Food and Beverage, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Ukko. To contact Ukko, visit ukko.us.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Ukko

Ukko: On a mission to solve food allergies and sensitivities, Ukko is a biotechnology startup founded in 2016 with headquarters in Israel and offices in Tel Aviv and Palo Alto, California. The company is leveraging cutting-edge technologies in immunology, computational biology, and plant science to develop innovative solutions for improving the lives of millions suffering from food allergies and disorders. The company recently secured a $40.00M Series B investment on 27th January 2021, with a diverse group of investors including Khosla Ventures, Fall Line Capital, Innovation Endeavors, Leaps by Bayer, PeakBridge Ventures, Skyviews Life Science, Continental Grain Company, and Marc Benioff. With a focus on biotechnology, food and beverage, and healthcare industries, Ukko demonstrates promising potential to address pressing global health challenges and drive innovations in the food and healthcare sectors.

Taxonomy: Biotech, Immunology, Computational biology, Plant science, Food allergies, Therapeutics, Allergy therapy, Molecular structure, Proteins, Immune response, Clinical validation, Biological mechanisms

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $40.00M 8
Khosla Ventures Fall Line Capital Innovation Endeavors
Khosla Ventures, Fall Line Capital +6
27 Jan 2021
Venture Round $7.70M 1
Khosla Ventures
Khosla Ventures
24 Jul 2017

Ukko Alternatives & Competitors

View All Alternatives
Ukko vs
Centaura
Centaura Switzerland

A game changer in human genome engineering to foster health and longevity for EVERYONE.

12 employees
Biotechnology, Health Care
Ukko vs
Ribon Therapeutics
Ribon Therapeutics United States

Pioneering Therapeutics Targeting Cellular Stress Pathways

Venture round
9 employees
Biotechnology, Health Care
Ukko vs
Outpace Bio
Outpace Bio United States

Revolutionizing Cell Therapy with Protein Design

Series B
74 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ukko

On a mission to solve food allergies and sensitivities
Ukko was founded in 2016.
Ukko is headquartered in Israel.
Ukko operates in Biotechnology, Food and Beverage and Health Care. Its work centres on Biotech, Immunology, Computational biology and Plant science.
Ukko has approximately 56 employees.
Ukko has completed 2 funding rounds, raising a total of $47.70M. The latest funding stage is Series B.
Top alternatives and competitors to Ukko include Centaura, Ribon Therapeutics, Outpace Bio, Immunaeon, Ventus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ukko and Centaura are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ukko, https://bouncewatch.com/company/ukko, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes